Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 12, 2025
- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -
Read more at globenewswire.comNASDAQ:DRTS (6/26/2025, 6:08:57 PM)
3.015
+0.02 (+0.5%)
NASDAQ:DRTSW (6/26/2025, 4:30:01 PM)
0.2498
0 (-0.04%)
Find more stocks in the Stock Screener
